263 related articles for article (PubMed ID: 33600217)
1. Polypharmacy in the Management of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: A Review and Update.
Baker M; Huefner JC; Bellonci C; Hilt R; Carlson GA
J Child Adolesc Psychopharmacol; 2021 Apr; 31(3):148-163. PubMed ID: 33600217
[No Abstract] [Full Text] [Related]
2. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders.
Osland ST; Steeves TD; Pringsheim T
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD007990. PubMed ID: 29944175
[TBL] [Abstract][Full Text] [Related]
3. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.
Cortese S; Adamo N; Del Giovane C; Mohr-Jensen C; Hayes AJ; Carucci S; Atkinson LZ; Tessari L; Banaschewski T; Coghill D; Hollis C; Simonoff E; Zuddas A; Barbui C; Purgato M; Steinhausen HC; Shokraneh F; Xia J; Cipriani A
Lancet Psychiatry; 2018 Sep; 5(9):727-738. PubMed ID: 30097390
[TBL] [Abstract][Full Text] [Related]
4. α2-Adrenergic Agonists or Stimulants for Preschool-Age Children With Attention-Deficit/Hyperactivity Disorder.
Harstad E; Shults J; Barbaresi W; Bax A; Cacia J; Deavenport-Saman A; Friedman S; LaRosa A; Loe IM; Mittal S; Tulio S; Vanderbilt D; Blum NJ
JAMA; 2021 May; 325(20):2067-2075. PubMed ID: 33946100
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review.
Chan E; Fogler JM; Hammerness PG
JAMA; 2016 May; 315(18):1997-2008. PubMed ID: 27163988
[TBL] [Abstract][Full Text] [Related]
6. Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.
May DE; Kratochvil CJ
Drugs; 2010; 70(1):15-40. PubMed ID: 20030423
[TBL] [Abstract][Full Text] [Related]
7. Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents.
Sikirica V; Haim Erder M; Xie J; Macaulay D; Diener M; Hodgkins P; Wu EQ
Pharmacoeconomics; 2012 Aug; 30(8):e1-15. PubMed ID: 22788263
[TBL] [Abstract][Full Text] [Related]
8. Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis.
Cortese S; Adamo N; Mohr-Jensen C; Hayes AJ; Bhatti S; Carucci S; Del Giovane C; Atkinson LZ; Banaschewski T; Simonoff E; Zuddas A; Barbui C; Purgato M; Steinhausen HC; Shokraneh F; Xia J; Cipriani A; Coghill D;
BMJ Open; 2017 Jan; 7(1):e013967. PubMed ID: 28073796
[TBL] [Abstract][Full Text] [Related]
9. A Naturalistic Comparison of Methylphenidate and Risperidone Monotherapy in Drug-Naive Youth With Attention-Deficit/Hyperactivity Disorder Comorbid With Oppositional Defiant Disorder and Aggression.
Masi G; Manfredi A; Nieri G; Muratori P; Pfanner C; Milone A
J Clin Psychopharmacol; 2017 Oct; 37(5):590-594. PubMed ID: 28806385
[TBL] [Abstract][Full Text] [Related]
10. The Effects of Long-Acting Stimulant and Nonstimulant Medications in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Meta-Analysis of Randomized Controlled Trials.
Cerrillo-Urbina AJ; García-Hermoso A; Pardo-Guijarro MJ; Sánchez-López M; Santos-Gómez JL; Martínez-Vizcaíno V
J Child Adolesc Psychopharmacol; 2018 Oct; 28(8):494-507. PubMed ID: 29897263
[TBL] [Abstract][Full Text] [Related]
11. Tricyclic antidepressants for attention deficit hyperactivity disorder (ADHD) in children and adolescents.
Otasowie J; Castells X; Ehimare UP; Smith CH
Cochrane Database Syst Rev; 2014 Sep; (9):CD006997. PubMed ID: 25238582
[TBL] [Abstract][Full Text] [Related]
12. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine.
Pringsheim T; Hirsch L; Gardner D; Gorman DA
Can J Psychiatry; 2015 Feb; 60(2):42-51. PubMed ID: 25886655
[TBL] [Abstract][Full Text] [Related]
13. Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder.
Martinez-Raga J; Knecht C; Szerman N; Martinez MI
CNS Drugs; 2013 Jan; 27(1):15-30. PubMed ID: 23160939
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults.
Wigal SB
CNS Drugs; 2009; 23 Suppl 1():21-31. PubMed ID: 19621975
[TBL] [Abstract][Full Text] [Related]
15. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.
Santosh PJ; Baird G; Pityaratstian N; Tavare E; Gringras P
Child Care Health Dev; 2006 Sep; 32(5):575-83. PubMed ID: 16919137
[TBL] [Abstract][Full Text] [Related]
16. A systematic review of combination therapy with stimulants and atomoxetine for attention-deficit/hyperactivity disorder, including patient characteristics, treatment strategies, effectiveness, and tolerability.
Treuer T; Gau SS; Méndez L; Montgomery W; Monk JA; Altin M; Wu S; Lin CC; Dueñas HJ
J Child Adolesc Psychopharmacol; 2013 Apr; 23(3):179-93. PubMed ID: 23560600
[TBL] [Abstract][Full Text] [Related]
17. Stepped Treatment for Attention-Deficit/Hyperactivity Disorder and Aggressive Behavior: A Randomized, Controlled Trial of Adjunctive Risperidone, Divalproex Sodium, or Placebo After Stimulant Medication Optimization.
Blader JC; Pliszka SR; Kafantaris V; Foley CA; Carlson GA; Crowell JA; Bailey BY; Sauder C; Daviss WB; Sinha C; Matthews TL; Margulies DM
J Am Acad Child Adolesc Psychiatry; 2021 Feb; 60(2):236-251. PubMed ID: 32007604
[TBL] [Abstract][Full Text] [Related]
18. The potential for misuse and abuse of medications in ADHD: a review.
Clemow DB; Walker DJ
Postgrad Med; 2014 Sep; 126(5):64-81. PubMed ID: 25295651
[TBL] [Abstract][Full Text] [Related]
19. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.
Garnock-Jones KP; Keating GM
Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548
[TBL] [Abstract][Full Text] [Related]
20. Electrophysiological and Clinical Predictors of Methylphenidate, Guanfacine, and Combined Treatment Outcomes in Children With Attention-Deficit/Hyperactivity Disorder.
Michelini G; Lenartowicz A; Vera JD; Bilder RM; McGough JJ; McCracken JT; Loo SK
J Am Acad Child Adolesc Psychiatry; 2023 Apr; 62(4):415-426. PubMed ID: 35963559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
